Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
← catalyst calendarNCT05952024 · readout in 977 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
57
Countries
Brazil, Puerto Rico, South Korea +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-16 | actual | When the study began enrolling |
| Primary completion | 2029-04-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-22 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B-Cell Lymphoma
Interventions
- Drug: Acalabrutinib — also filed as CALQUENCE®
- Biological: Rituximab
Primary outcome
what the primary-completion date above is the date OFPercentage of patients with Grade 3 to 4 treatment emergent adverse events (TEAEs)
measured Cycle 1 Day 1 (Cycles 1 to 8 is 21 days and Cycles 9 to 28 is 28 days) through End of treatment EoT [30 days of discontinuation] (Up to 3.5 Years)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed